Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$4.8M
Filings
35
Firms Hired
1
Active Period
2019–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · third_quarter · Firm: LANTHEUS HOLDINGS, INC.
Legislation (H.R. 1199 and S.1544) on HOPPS separate payment for diagnostic radiopharmaceuticals Medicare 2025 Hospital Prospective Payment System proposal for separate payment for diagnostic radiopharmaceuticals above $630/day cost threshold
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · third_quarter · Firm: LANTHEUS HOLDINGS, INC.
Legislation (H.R. 1199 and S.1544) on HOPPS separate payment for diagnostic radiopharmaceuticals Medicare 2025 Hospital Prospective Payment System proposal for separate payment for diagnostic radiopharmaceuticals above $630/day cost threshold
Client expense: $140,000 · Firm income: —
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · first_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $400,000 · Firm income: —
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · first_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $400,000 · Firm income: —
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · second_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $155,000 · Firm income: —
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · second_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $155,000 · Firm income: —
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · first_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $320,000 · Firm income: —
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2024 · first_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $320,000 · Firm income: —
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · fourth_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $70,000 · Firm income: —
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · fourth_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $70,000 · Firm income: —
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · third_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $70,000 · Firm income: —
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · third_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $70,000 · Firm income: —
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · second_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $110,000 · Firm income: —
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · second_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $110,000 · Firm income: —
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · second_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $110,000 · Firm income: —
Matched citations: H.R. 1199
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · second_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. H.R. 1199 and S.1544)
Client expense: $110,000 · Firm income: —
Matched citations: S.1544
Facilitating Innovative Nuclear Diagnostics Act of 2023
2023 · first_quarter · Firm: LANTHEUS HOLDINGS, INC.
Medicare HOPPS separate payment for high-precision diagnostic radiopharmaceuticals (e.g. HR 1199)
Client expense: $290,000 · Firm income: —
Matched citations: HR 1199
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · fourth_quarter · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharmaceuticals
Client expense: $75,000 · Firm income: —
Matched citations: H.R.4479
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: LANTHEUS HOLDINGS, INC.
H.R. 7667, S. 4348; and S. 4333 - Regulatory status for imaging contrast agents
Client expense: $75,000 · Firm income: —
Matched citations: H.R. 7667
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · fourth_quarter · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharmaceuticals
Client expense: $75,000 · Firm income: —
Matched citations: S.2609
H.R. 7667, S. 4348; and S. 4333 - Regulatory status for imaging contrast agents
Client expense: $75,000 · Firm income: —
Matched citations: S. 4333
H.R. 7667, S. 4348; and S. 4333 - Regulatory status for imaging contrast agents
Client expense: $75,000 · Firm income: —
Matched citations: S. 4348
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · third_quarter · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharmaceuticals
Client expense: $70,000 · Firm income: —
Matched citations: H.R.4479
Food and Drug Amendments of 2022
2022 · third_quarter · Firm: LANTHEUS HOLDINGS, INC.
FDA user fee reauthorization H.R. 7667, S. 4348; and S. 4333 (regulatory status for imaging contrast agents)
Client expense: $70,000 · Firm income: —
Matched citations: H.R. 7667
Facilitating Innovative Nuclear Diagnostics Act of 2021
2022 · third_quarter · Firm: LANTHEUS HOLDINGS, INC.
H.R.4479 and S.2609 - Facilitating Innovative Nuclear Diagnostics (FIND) Act Medicare Hospital Outpatient Prospective Payment System policy packaging for diagnostic radiopharmaceuticals
Client expense: $70,000 · Firm income: —
Matched citations: S.2609
Source: Senate LDA